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Background: Our previous study showed that fatty acids extract obtained from CLA-enriched egg yolks (EFA-CLA)
suppressed the viability of MCF-7 cancer cell line more effectively than extract from non-enriched egg yolks (EFA).
In this study, we analysed the effect of EFA-CLA and EFA on transcriptome profile of MCF-7 cells by applying the
whole Human Genome Microarray technology.
Results: We found that EFA-CLA and EFA treated cells differentially regulated genes involved in cancer
development and progression. EFA-CLA, compared to EFA, positively increased the mRNA expression of TSC2 and
PTEN tumor suppressors as well as decreased the expression of NOTCH1, AGPS, GNA12, STAT3, UCP2, HIGD2A, HIF1A,
PPKAR1A oncogenes.
Conclusions: We show for the first time that EFA-CLA can regulate genes engaged in AKT/mTOR pathway and
inhibiting cell cycle progression. The observed results are most likely achieved by the combined effect of both:
incorporated CLA isomers and other fatty acids in eggs organically modified through hens’ diet. Our results
suggest that CLA-enriched eggs could be easily available food products with a potential of a cancer
chemopreventive agent.
Keywords: AKT/mTOR pathway, CLA-enriched egg yolks, DNA microarray, Cancer chemoprevention, MCF-7 cancer
cells, Transcriptome, SFA/MUFAIntroduction
Conjugated linoleic acid (CLA) term includes several
isomers of linoleic acid (18:2), naturally present in
ruminant and dairy products, due to the activity of the
rumen microflora [25, 30]. In numerous studies, CLA
was shown to have several beneficial properties on
human health. Researchers examined its effect on stimu-
lating the immune system [1], reducing cancerogenesis
[32, 52], atherogenesis [34], diabetes, and obesity [54].
However, most of the available literature was focused on
the activity of isolated, pure substances. In addition,* Correspondence: aneta.koronowicz@gmail.com
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naturally occurring CLA are relatively too low to effect-
ively impact human health [27]. The recommended effect-
ive dose of CLA was estimated at least 1.5–3.5 g/day [13],
while natural ruminant products contain between 1.2
and 12.5 mg per gram of fat [25, 30, 47, 78] and in
poultry CLA concentration remains relatively low, at
0.6 to 0.9 mg per gram of fat [13]. Enhancing CLA
concentration in food products such as eggs, chosen
dairy products/yogurts, and meat could then become
an alternative to synthetic CLA supplements. Indeed,
studies have shown an easy incorporation of CLA into
eggs of chickens by diet fortification [11, 65, 74] and
that CLA-enriched eggs meet the requirements of
functional food [24].le is distributed under the terms of the Creative Commons Attribution 4.0
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from CLA-enriched food products on cancer cells
[16, 46]. Our previous study showed that FA extracts
obtained from CLA-enriched egg yolks (EFA-CLA)
suppressed the viability of MCF-7 cancer cell line
more effectively than the extracts from non-enriched
egg yolks (EFA) [32]. To analyze the potential mo-
lecular mechanism, we decided to compare the effects
of both extracts on MCF-7 cells transcriptome profile.
The whole-genome DNA microarray technology has
become a very powerful tool to analyze global gene ex-
pression profiles, and in multiple studies, it has been
shown to be an effective method for detecting genomic
variation of closely related samples. Finally, we identified
and analyzed differently expressed genes based on fam-
ily, molecular functions, biological processes, cellular
components, or pathways. As suggested in this article,
relationships between studied genes require a confirm-
ation at protein level; nevertheless, the microarray re-
sults are a valuable and multi-faceted source of
information for other scientists and a foundation for fur-
ther in vivo research [67].
Methods
Hens’ and eggs’ management
The Animal Ethics Committee of the National Institute
of Animal Production (Poland) approved all experiments
involving animals (approval number: 851/2011). All ap-
plicable international, national, and/or institutional
guidelines for the care and use of animals were followed.
Forty-eight Isa Brown laying hens (26 weeks old) were
housed in a controlled room under 14/10 h light/dark cycle,
given free access to water and commercial starter diet (‘DJ’
feed). After a 1-week adaptation period, an equal number of
hens was randomly allocated to the control or experimental
group for 4 months of the experiment. Diets (Additional file
1: Table S1) were calculated to provide 2700 kcal/kg and
17 % crude protein. The 0.75 % dietary CLA (TONALIN
FFA 80, BASF Company, Germany) concentration was
based on previously determined formula [24] and contained
80 % CLA in 50:50 ratio for cis-9,trans-11 and trans-10,cis-
12 isomers. Eggs were collected daily for the period of
10 weeks and stored at 4 °C. Yolks were separated from al-
bumen, homogenized with rotary homogenizer, and frozen
at −20 °C. Samples were then lyophilized (Martin Christ
Model Alpha 1–4, Germany) and again stored at −20 °C.
The total dry matter was determined by oven drying method
[3] and the total fat content was determined by Soxhlet
method (Soxtec Avanti’s 2050 Auto Extraction Unit, Tecator
Foss, Sweden) using petroleum ether as a solvent [23].
Fatty acids extraction and GC/MS analysis
Lipids from control and CLA-enriched yolks were ex-
tracted by using modified Folch method [22]. One gramper liter of butylated hydroxytoluen (BHT) was used as an
antioxidant. Briefly, after overnight incubation with
chloroform/methanol (2:1) solution, samples were filtrated
and mixed with 4 mL of 0.88 % sodium chloride solution
to obtain phase separation. Chloroform lipids layer was
then carefully dried under nitrogen. Ten milligrams of
each lipid extract was subjected to saponification (20 min,
60 °C) with 0.5 M KOH/methanol followed by methyla-
tion with 14 % (v/v) BF3/methanol (15 min, 60 °C) and ex-
traction with hexane. The obtained fatty acid methyl
esters (FAME) were analyzed by GC/MS (Additional file
2: Table S2). The profile of EFA-CLA and EFA was
expressed as percentage (%) of relative area, obtained by
area normalization (FA peak area relative to chromato-
gram total area). For the treatment, lipid extracts were
subjected to the basic hydrolysis (0.5 M KOH, 60 °C,
15 min) and extracted with hexane. The free fatty acids
were then dissolved in ethanol at the stock concentration
1 g/mL and stored under nitrogen in the temperature of
−20 °C.
Cell culture and treatment
Human breast adenocarcinoma cell line MCF-7 (ATCC®
HTB22TM) was purchased from the American Type Cul-
ture Collection. Cells were cultured according to the
manufacturer’s procedure. Cells were seeded in culture
plates (BD Biosciences) for 24 h. After that time, grow-
ing medium was replaced by a medium containing (a)
fatty acid extract from CLA-enriched egg yolks (EFA-
CLA) and (b) fatty acids extract from non-enriched egg
yolks (EFA), both at the concentration of 0.5 mg/mL.
We used (c) cell cultures only in growth medium (empty
control (EC)) and (d) cell cultures treated with only a
solvent of fatty acids (ET-ethanol) at final concentration
0.1 %, as a negative control (NC).
Cell proliferation
Cell proliferation was determined with 5′-bromo-2′-de-
oxy-uridine (BrdU) Labeling and Detection Kit III
(Roche), according to manufacturer’s instruction.
Microarray analysis of gene expression profile
Whole Human Genome Microarrays containing about
50 000 probes (Agilent Technologies, USA) were used to
establish the expression profile of each tested sample.
Total RNA was isolated from cells using RNA isolation
kit (A&A Biotechnology, Poland). RNA quantity was
measured with NanoDrop (NanoDrop Technologies,
USA). The analysis of its quality and integrity was per-
formed with BioAnalyzer (Agilent, USA). Only samples
with RNA integrity number (RIN) ≥8.0 were included in
the analysis which was performed using SurePrint G3
Human Gene Expression 8x60K v2 Microarray. Each
slide contained eight microarrays representing about 50
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two-color (Agilent, USA) was used to amplify and label
target RNA to generate complementary RNA (cRNA)
for oligo microarrays used in gene expression profiling.
The experiment was performed using a common refer-
ence design, where the common reference was a pool of
equal amounts of RNA from control cells. On each of
two-color microarrays, 300 ng of cRNA from the pool
(labeled Cy3) and 300 ng of cRNA (labeled Cy5) were
hybridized. In total, 12 microarrays were run—three for
each experimental group. Microarray hybridization was
performed with the Gene Expression Hybridization Kit
(Agilent Technologies, USA), according to the manufac-
turer’s protocols. RNA Spike In Kit (Agilent Technolo-
gies, USA) was used as an internal control. Acquisition
and analysis of hybridization intensities were performed
using the Agilent DNA microarray scanner. Data were
extracted and background was subtracted using standard
procedures contained in the Agilent Feature Extraction
(FE) Software version 10.7.3.1. FE performs Lowess
normalization. Samples underwent quality control and
the results showed that each sample had a similar QC
metric profile. The next step was filtering probe sets by
flags to remove poor quality probes (absent flags).
Microarray data were deposited at the Gene Expression
Omnibus data repository under the number GSE65397
and followed MIAME requirements. To identify signal-
ing pathways and gene functions, the microarray data
were analyzed using Panther Classification System—an
online database.
RT and real-time PCR analysis
Reverse transcription was performed using 1 μg of total
RNA isolated from the cells by using the Maxima first
Strand cDNA Synthesis kit for RT-qPCR (Thermo Sci-
entific). A quantitative verification of genes was per-
formed using the CFX96 Touch™ Real-Time PCR
Detection System instrument (Bio-Rad), utilizing the
SYBR Green Precision Melt Supermix kit (Bio-Rad).
Conditions of individual PCR reactions were optimized
for given pair of oligonucleotide primers (Additional file
3: Table S3). Basic conditions were as follows: 95 °C for
10 min, 45 PCR cycles at 95 °C, 15 s; 59 °C, 15 s; 72 °C,
15 s, followed by melting curve analysis (65–97 °C with
0.11 °C ramp rate and five acquisitions per 1 °C). Results
were normalized using at least two reference genes
(GAPDH, HPRT1, ACTB, or HSP90AB1) and were calcu-
lated using the 2−ΔΔCT method [39].
Statistical analysis
Each treatment included three replicates and the experi-
ment was repeated three times. Statistical analysis for
microarrays was performed using Gene Spring 12.6.1 soft-
ware (Agilent, USA). Statistical significance of thedifferences was evaluated using a one-way ANOVA and
Tukey’s HSD Post hoc test (p < 0.05). A multiple testing
correction was performed using Benjamini and Hochberg
false discovery rate (FDR) <5 %. Other experiments were
assessed by Student’s t tests.Results
Bird performance and egg composition
There were no significant differences in egg production
between hens as well as egg characteristics [33]. Fatty
acid profile in CLA-enriched egg yolks was significantly
affected by dietary CLA fortification (Fig. 1). Both CLA
isomers were found incorporated into the yolk, and their
concentration did not reflect their initial proportion in
the experimental diets (Additional file 1: Table S1), with
the preference for the cis-9,trans-11 isomer. Compared
to the control, feeding with 0.75 % of dietary CLA sig-
nificantly increased (p < 0.001) total SFA concentration
at the expenses of MUFA (p < 0.001) (Fig. 1 and [33]).Cell proliferation
EFA-CLA extract at a concentration of 0.5 mg/mL sup-
pressed MCF-7 cell proliferation more effectively than
the extract from non-enriched egg yolks. Specifically,
treatment with EFA-CLA reduced the cell proliferation
by approximately 40 % compared to the negative con-
trol, while EFA reached 20 % (Fig. 2). Moreover, this ef-
fect was weaker for estrogen-negative MDA-MB-231
(Additional file 4: Figure S12) and not observed for a
non-tumorigenic MCF-10A cell line (Fig. 3).Effect of applied treatments on MCF-7 cell line transcrip-
tome profile
The analysis was performed on 1589 transcripts, of
which 160 were differently expressed between EFA-CLA
and EFA studied groups (Fig. 4 and Additional file 5:
Table S4). We omitted 21 genes, which could have been
directly affected by the solvent (ET) leaving 139 genes
(Additional file 6: Table S10). Further analysis showed
69 transcripts shared by all three comparison groups:
EFA-CLA vs. EFA, NC vs. EFA-CLA, and NC vs. EFA
and 36 transcripts shared by EFA-CLA vs. EFA and NC
vs. EFA. We determined 34 transcripts unique only to
EFA-CLA vs. EFA. Among those, 11 were uncharacter-
ized in available databases. Finally, we identified 18
(underlined) that, according to the available data, can be
linked to cancer development and/or progression and
which are involved in important cellular processes in-
cluding regulation of cell cycle, apoptosis, or cell metab-
olism (Table 1). For those, the differences in expression
between EFA and NC were statistically insignificant
(Additional file 7: Table S5).
Fig. 1 Effect of dietary CLA on relative (%) fatty acids composition of egg yolks. Statistical significance of treatment: *p < 0.05;
**p < 0.01; ***p < 0.001
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To validate microarray data, we selected eight random
genes from EFA-CLA vs. EFA comparison group:
NOTCH1, HIGD2A, PPKAR1A, UPC2, NAP1L1, CAM-
SAP2, PPP2R5E, and TSC2 (p < 0.05, Table 2). Our ana-
lysis showed a significant decrease in the messenger
RNA (mRNA) expression of NOTCH1, HIGD2A,
PPKAR1A, and UCP2 and an increase in the expression
of CAMSAP2, PPP2R5E, and TSC2 genes due to the
EFA-CLA treatment. Interestingly, only RT-qPCR resultsFig. 2 Effect of EFA-CLA on MCF-7 cells proliferation. Values are expressed
significance was based on Student’s t test *p < 0.05 vs. NC and ^p < 0.05 vsfor NAP1L1 exhibited changes in the opposite direction
than the microarray.
GO molecular complete analysis
Next, we examined the Gene Ontology (GO) for EFA-
CLA vs. EFA differently regulated genes, using Panther
Classification System. Results obtained from analysis of
the signaling pathways, biological processes, molecular
functions, and protein classes are presented in supplemen-
tary material (Additional file 8: Table S6, Additional file 9:as means ± SEM for the N ≥ 9, standarized to NC as 100 %. Statistical
. EFA
Fig. 3 Effect of EFA-CLA on MCF-10A cells proliferation. Values are expressed as means ± SEM for the N≥ 9, standarized to NC as 100 %. Statistical
significance was based on Student’s t test *p < 0.05 vs. NC and ^p < 0.05 vs. EFA
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11: Table S9).
Effect of EFA-CLA on oncogenic pathways
In addition to signaling pathways listed in Additional file
8: Table S6, we aimed to study the connections between
all the transcripts from Table 1, especially in terms of
oncogenic pathways (Fig. 5) [79]. Our results showed that
EFA-CLA treatment affected the downstream genes of the
mammalian target of rapamycin (mTOR) signaling path-
way. The increased mRNA expression of PTEN, PPP2R5E,
and TSC2 and decreased expression of GNA12, UPC2,Fig. 4 Analysis of differently expressed transcripts between experimental gAGPS, ANAX5A, and HIF1A, together with observed
reduced proliferation of MCF-7, suggest that EFA-CLA
negatively regulates AKT/mTOR pathway.
Discussion
Breast cancer is one of the most common malignan-
cies among women [21]; however, despite extensive
research, the cellular processes that lead to carcino-
genesis have not yet been fully explained. In the
current research, we chose the estrogen receptor-
positive (ER+) MCF-7 breast cancer cell line—the
most studied cellular model of breast cancer [26, 59, 73].roups
Table 1 The list of the differently regulated EFA-CLA vs. EFA specific transcripts in MCF-7 cell line
Gene Symbol Adjusted p values FC value Gene name
NOTCH1 0.0146 −2.63 Notch homolog 1, translocation-associated
AGPS 0.0424 −2.19 Alkylglycerone phosphate synthase
GNA12 0.0009 −1.56 Guanine nucleotide binding protein (G protein) alpha 12
HIF1A 0.0184 −1.56 Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix
transcription factor)
STAT3 0.0088 −1.32 Signal transducer and activator of transcription 3
(acute-phase response factor)
UCP2 0.0083 −1.29 Uncoupling protein 2 (mitochondrial, proton carrier)
HIGD2A 0.0089 −1.27 HIG1 hypoxia inducible domain family, member 2A
WASH1 0.0038 −1.27 WAS protein family homolog 1
BIN3 0.0477 −1.16 Bridging integrator 3
PRKAR1A 0.0462 −1.14 Protein kinase, cAMP-dependent, regulatory, type I, alpha
NDUFB11 0.0105 −1.13 NADH dehydrogenase (ubiquinone) 1 beta subcomplex,
11, 17.3 kDa
ANXA5 0.0311 −1.05 Annexin A5
SMS 0.0399 1.08 Spermine synthase
PPP2R5E 0.0009 1.13 Protein phosphatase 2, regulatory subunit B', epsilon isoform
NAP1L1 0.0335 1.14 Nucleosome assembly protein 1-like 1
PTEN 0.0382 1.15 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and
dual-specificity protein phosphatase PTEN
LOC646214 0.0213 1.16 p21 protein (Cdc42/Rac)-activated kinase 2 pseudogene
LMCD1 0.0067 1.21 LIM and cysteine-rich domains 1
CAMSAP2 0.0174 1.23 Calmodulin regulated spectrin-associated protein family, member 2
TSC2 0.0177 1.26 Tuberous sclerosis 2
FLJ45139 0.0406 1.33 FLJ45139 protein
CHSY3 0.0399 1.72 Chondroitin sulfate synthase 3
OVOS 0.0403 1.72 Ovostatin
SCD 0.19 −1.18NS Stearoyl-CoA desaturase (delta-9-desaturase)
Statistical significance of treatment: p < 0.05; NS p > 0.05; bolded genes are to be associated with cancer
Table 2 The validation of microarray results with RT-qPCR in MCF-7 cell line (EFA-CLA vs. EFA)
Gene
symbol
Adjusted
p values
FC value
RT-qPCR
FC value
Microarray
Gene name
NOTCH1 0.0022 −2.02 −2.63 Notch homolog 1, translocation-associated
HIGD2A 0.0121 −1.75 −1.27 HIG1 hypoxia inducible domain family,
member 2A
PRKAR1A 0.0047 −1.58 −1.14 Protein kinase, cAMP-dependent, regulatory,
type I, alpha
UCP2 0.0023 −1.53 −1.29 Uncoupling protein 2 (mitochondrial, proton
carrier)
NAP1L1 0.0023 −1.37 1.17 Nucleosome assembly protein 1-like 1
CAMSAP2 0.0031 1.57 1.23 Calmodulin regulated spectrin-associated
protein family, member 2
PPP2R5E 0.0035 1.72 1.13 Protein phosphatase 2, regulatory subunit B',
epsilon isoform
TSC2 0.0001 1.85 1.26 Tuberous sclerosis 2
Statistical significance of treatment: p < 0.05
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Fig. 5 Potential interactions between differently regulated genes treated with EFA-CLA in MCF-7 cells (listed in Table 1)
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(ER+) breast cancers are the most frequently diagnosed
breast cancer subtype.
CLA is an extensively studied compound, and research
findings showed a variety of possible beneficial effects of
dietary CLA on human health. In addition, some of the
molecular aspects of CLA mechanisms of action have
been already described, and to our knowledge, Murphy
et al. [50] applied microarray technique to show the ef-
fects of CLA isomers on the global gene expression
using Caco-2 cells. However, most of published results
are based on studying pure, isolated isomers which may
not reflect the effect of a food product naturally
enriched in CLA. Thus, our research would be the first
to address the effects of the extract from CLA-enriched
egg yolks on a breast cancer cell model in a wide
spectrum of the whole human genome.
Our previous experiments showed that EFA-CLA ex-
tract suppressed the viability of MCF-7 breast cancer cell
line more effectively than extract from non-enriched egg
yolks [32]. Our current study supports those findings
not only for estrogen receptor-positive MCF- 7 but also
for estrogen receptor-negative MDA-MB-231; however,
the EFA-CLA effect was most notable for MCF-7 (Fig. 2and Additional file 4: Figure S12), which we proposed to
be associated with affected mTOR signaling pathway [8].
In addition, we also performed experiments on commer-
cially available and described as a non-tumorigenic
MCF-10A cell line (ATCC). Interestingly, we did not ob-
serve a decreased proliferation in that cell line after
treatment with tested fatty acids (Fig. 3). Some authors
recommend caution when using MCF-10A cell line as
non-transformed human breast epithelial cells in car-
cinogenesis research. They point out their potential for
morphological and phenotypic transformation [56].
However, it should be noted that, to some extent, this
could be due to the modification of the cell line micro-
environment, including culture conditions, presence of
serum, and used medium [53, 76].
In the present manuscript, we discuss selected genes,
which expression differs the most between cells treated
with FA from CLA-enriched and non-enriched egg yolks
(Table 1), specifically, in terms of their potential signifi-
cance in the neoplastic process. Based on a scheme of
the interactions between those genes (Fig. 5), we pointed
the anti-proliferative and pro-apoptotic properties of
EFA-CLA, specifically through the regulation of AKT/
mTOR signaling pathway. mTOR interacts with several
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mTOR complex 1 (mTORC1) and 2 (mTORC2) of
which mTORC1 is currently better characterized. mTOR
is a central controller of protein synthesis, cell growth,
cell proliferation, and cell viability [37]. Several compo-
nents of the PI3K/PTEN/AKT/mTOR pathway (Fig. 5)
are frequently mutated in human cancers.
Most notably, our results showed that treatment of
MCF-7 cells with EFA-CLA (compared to EFA) in-
creased the mRNA expression of known tumor suppres-
sors, such as TSC2, PTEN, PPP2R5E, and LMCD1. TSC2
complex is a key upstream regulator of mTORC1, and it
constitutes of two proteins, TSC1 and TSC2, that inter-
acts with each other. Mutations in either of them result
in the development of the tuberous sclerosis complex
(TSC), characterized by the growth of benign tumors in
multiple vital organs [29]. Reduced expression of TSC2
was determined in the invasive breast cancer compared
to normal mammary epithelium [45]. Another mTOR
pathway inhibitor, PTEN, was also found up-regulated.
PTEN is a p53-regulated tumor suppressor, which tran-
scription can be enhanced by p53 protein—acting as a
transcription factor. Although our microarrays did not
show statistically significant change in TP53 mRNA ex-
pression in the EFA-CLA cells vs. EFA group, additional
Western blot analysis clearly showed an accumulation of
p53 at the protein levels in the EFA-CLA treated cells
(data not shown). PTEN is one of the most frequently
mutated genes in various human cancers [9, 17, 70], in-
cluding breast cancers, and is linked to aggressive tu-
mors [64]. Information on PPP2R5E is limited, but it has
been suggested as a potential negative regulator of PI3K/
AKT signaling (2016). It has been also found to act as a
tumor suppressor in breast cancer [19] and gastric can-
cer cells [38].
During our analysis, we have also found other genes
potentially associated with PI3K/AKT/mTOR pathway,
which were down-regulated in cells: AGPS, ANXA5,
STAT3, NOTCH1, PRKAR1A, and HIF1A (Table 1), after
the treatment with EFA-CLA. Whether observed de-
crease in gene expression is the cause or the result of in-
hibition of AKT/mTOR pathway requires further study.
Zhu et al. [77] showed that phosphorylation of AKT1 in
glioma and hepatic carcinoma cell lines was reduced
simultaneously with AGPS silencing, whereas Benjamin
et al. [6] showed that silencing of AGPS in breast cancer
(including MCF-7) and melanoma cells manifested in a
life-time reduction of cancer cells viability, tumor
growth, and invasiveness. Although we did not find a
direct link between ANXA5 and AKT/mTOR pathway
(Fig. 5), its up-regulation may be a predictive factor for
tumor stage and clinical outcome of colorectal cancer
[71]. ANXA5 has been also found in a group of pro-
apoptotic genes [48]. These data may suggest that theexpression of ANXA5 could be dependent on the ex-
pression profile of other superior genes being a part of
anti-tumor response of cells. In our study, we show a
significant down-regulation of STAT3 and NOTCH1
gene under the influence of EFA-CLA. Phosphorylated
STAT3 is being observed in nearly 70 % of human can-
cers. Acting as an oncoprotein, it is constitutively acti-
vated in many primary human tumors, being activated
by a number of different cytokines as well as oncopro-
teins, i.e., Src and Ras. NOTCH1 is associated with PI3K
and PI3K-dependent activation of AKT1. It has been
shown to play a role in growth, proliferation, and inhib-
ition of apoptosis [10, 58]. It has been also reported that
Hes1, NOTCH1’s downstream target protein, negatively
regulates PTEN expression [51]. A fly model of tumori-
genesis induced by NOTCH1 showed a synergism of
NOTCH1 signaling and PI3K/AKT pathway, suggesting
that the interplay between these two signaling pathways
was conserved during the evolution process.
PRKAR1A has been found to be down-regulated in
MCF-7 cells, due to the treatment with EFA-CLA. Infor-
mation about PRKAR1A in available literature is am-
biguous. Some studies have shown its up-regulation in
many tumors, including breast cancer [7, 40, 41], sug-
gesting its role in cell cycle regulation, growth, and/or
proliferation. Other studies have pointed its tumor sup-
pressing properties in osteosarcoma [49] and follicular
thyroid cancer [55]. Due to EFA-CLA treatment, we de-
termined a reduction in the mRNA expression of UCP2,
which belongs to the family of mitochondrial carriers.
Significant amount of studies is available on UCP2, but
its functions are still under debate. It has been recently
proposed to control routing of mitochondrial substrates
[20, 69]. The overexpression of UCP2 has been shown in
various tumors, including breast cancer [44]. Some data
reveal that up-regulation of UCP2 may facilitate an in-
creased chemoresistance as well as cancer adaptation to
oxidative stress via mitochondrial suppression of reactive
oxygen species (ROS) [4, 15, 18]. Sayeed et al. [60] have
shown that UCP2 gene silencing rapidly led to the in-
duction of apoptosis and differentiation in breast cancer
cells, concurrent with reduced cell survival and prolifer-
ation. These results may be supported by numerous
studies reporting evidences suggesting a correlation be-
tween oxidative stress and breast cancer, due to mito-
chondrial dysfunction [57]. Being the source of ROS,
mitochondria are particularly exposed to potential oxida-
tive DNA damage. Several studies have determined a
higher rate of mitochondrial DNA (mtDNA) mutations
in breast tumor tissue, specifically, they identified som-
atic mutations in the D-loop region as, probably, the
major factor leading to decreased mtDNA level in breast
tumors and indicating a poor prognosis [36]. Recent re-
sults have shown that a reduced number of mtDNA
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progression [66, 75] and mtDNA content might be po-
tentially used as a tool to predict prognosis. Interest-
ingly, in our unpublished studies on prostate cancer cells
and melanoma, we determined a significant increase in
the levels of mtDNA when treating with EFA-CLA ex-
tracts (compared to EFA).
We also determined a down-regulation of HIGD2A, a
subunit of the cytochrome C oxidase (COX, complex IV).
However, little is known about its mechanism of action. A
study presented by An et al. [2] on HIGD1A, another
member of HIG1 gene family, showed that expression of
HIGD1A is directly dependent on binding of HIF-1α to
HRE (hypoxia-response element) site at −32 bp in the
HIG1D1A promoter. Transfecting RAW264.7 cell line
with HIGD1A under hypoxia condition promoted cell sur-
vival, whereas silencing the endogenous gene with siRNA
resulted in hypoxia-induced apoptosis. The authors have
proposed the inhibition of cytochrome C release and the
reduction of caspases as a potential mechanism. They also
obtained similar results for HIGD2A. It should be noted
that similarity between HIG1 gene family members might
have influenced obtained microarray results as probe
specificity for gene isoforms is limited [35]. Interestingly,
in our unpublished results on prostate cancer cells and
melanoma, we determined a down-regulation of HIF-1α,
after treatment with EFA-CLA. In our present study, we
also observed down-regulation of HIF-1α in MCF-7 cells
after EFA-CLA treatment, which is a positive signal con-
firming the anti-proliferative activity of EFA-CLA in the
AKT/mTOR pathway (Fig. 5). HIF-1α is responsible for
the activation of transcription of various genes, such as
VEGF, EDN1, or CDKN1A, which are involved in cell
cycle regulation, neovascularization, and metastasis [62].
Overexpression of HIF-1α correlates with an advanced
tumor stage and poor survival [63, 68]. Majumder et al.
[43] have demonstrated that the expansion of AKT-driven
prostate epithelial cells requires mTOR-dependent sur-
vival signaling and activation of HIF-1α.
Finally, our results showed a down-regulation of
GNA12 mRNA expression after the treatment with EFA-
CLA. Although we did not find a direct association with
mTOR, GNA12 has been found to participate in onco-
genesis and metastasis in pathological conditions [28].
Kim et al. [31]), while studying breast cancer cells, pro-
posed that GNA12 up-regulates the activity of matrix
metalloproteinase (MMP)-2 via p53-dependent manner
and promotes malignant phenotypic conversion of this
cancer cells. A recent study supported those findings [12].
Their results also show that GNA12 stimulates the expres-
sion and activity of tumor promoting cytokines IL-6 and
IL-8 and MMP-2 via binding and activation of NF-kB.
Although in current manuscript we focused on differ-
ences between the CLA-enriched (CLA-EFA) and non-enriched egg (EFAs), attached data (database GSE65397)
suggest that EFAs can change the gene expression pro-
file as well; however, they are unable to suppress the cell
proliferation as efficiently as CLA-EFA can. The analysis
of MCF-7 transcriptomes revealed that some of the ob-
served changes may not be solely caused by CLA iso-
mers present in the pool of other fatty acids identified in
the enriched egg yolk. As shown in Fig. 1, the incorpor-
ation of CLA was accompanied by significant changes in
the general FA profile of egg yolk. The most notable was
an increase in total SFA concentration at the expense of
MUFA. Our calculations showed that the altered SFA/
MUFA ratio can affect the expression of some genes in-
cluding HIGD2A and SMS (Additional file 12: Table
S11) suggesting that the changed FA ratio in EFA-CLA
extract could be responsible, at least in part, for the spe-
cific response of the cancer cells (Fig 2). It seems there-
fore that our functional products, obtained through the
process of modification of hens’ diet, may show specific
features determined by both the presence of CLA and
altered SFA/MUFA ratio. This may also suggest that
CLA-enriched eggs cannot be simply replaced with a
synthetic CLA supplements.
Although available literature on effects of CLA on
other FAs is limited, some authors have shown that
treatment of cells with synthetic CLA increased the
SFA/MUFA ratio in cell culture [14, 72]. As potential
explanation, authors suggested that CLA could reduce
the expression of SCD gene, which is responsible for
conversion of SFA into MUFA. Interestingly, overexpres-
sion of SCD was associated with increased cancer cell
proliferation, both in vitro for breast, prostate and lung
cancer cells as well as in vivo [5, 14]. Our results showed
a decreasing tendency for SCD mRNA for EFA-CLA vs.
EFA treatment groups (Table 1); however, these results
were statistically non-significant. Nevertheless, compari-
son with the negative control revealed a significant re-
duction in SCD expression for EFA-CLA at the level of
transcription (Additional file 7: Table S5). It should be
noticed, however, that the SCD mRNA levels does not
necessarily correspond with this enzyme activity that has
been shown by Choi et al. [14] for both MDA-MB- 231
and MCF-7 cells treated with synthetic cis-9, trans-11
and trans-10, cis-12 CLA isomers. SCD has been also re-
ported to be involved in mTOR pathway. Scaglia and
Igal [61] have showed that the down-regulation of SCD
reduces the activity of AKT in A549 cell line (SCD-ab-
lated A549 cells). In addition, Luyimbazi et al. [42] have
observed an increase in SCD protein expression when
using activators of mTOR pathway in both MCF-7 (ER+)
and MDA-MB-231 (ER−) cell lines, while the use of se-
lective mTOR inhibitors showed an opposite effect. All
these data may suggest that the observed decrease in
MCF-7 proliferation in the presence of EFA-CLA could
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pathway and reduced expression of SCD and other genes
involved in mTOR pathway (database GSE65397). How-
ever, the role of CLA, other egg FAs, and the altered SFA/
MUFA ratio in mTOR-dependent down-regulation of cell
proliferation needs further studies.
Although some of our results may require to be con-
firmed at protein levels, the microarrays are a valuable
and multi-faceted source of information and may explain
the adequacy of further in vivo research, according to 3R
principles (replacement, reduction, and refinement).
Conclusions
In summary, our study presents the first evidence that the
fatty acids extracts from CLA-enriched egg yolks (EFA-
CLA) can affect transcriptome of MCF-7 cancer cells and
inhibit their proliferation. We found this effect to be
accompanied by changes in gene expression associated
with down-regulation of AKT/mTOR signaling pathway.
EFA-CLA increased expression of TSC2 and PTEN tumor
suppressors as well as decreased the expression of onco-
genes including NOTCH1, AGPS, GNA12, STAT3, UCP2,
HIGD2A, HIF1A, and PPKAR1A. The observed results are
most likely achieved by the combined effect of both incor-
porated CLA isomers and other fatty acids in eggs organ-
ically modified through hens’ diet. It seems, therefore, that
in contrast to synthetic CLA supplements, CLA-enriched
eggs with an altered SFA/MUFA ratio could be easily
available food products with a potential of a cancer
chemopreventive agent. Although this concept needs fur-
ther in vivo studies, it is clear that our microarray-derived
results are a rich source of information on pathways in
which fatty acids from CLA-enriched egg yolks can modify
the response of the cancer cells at the level of transcription.
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